Regencell Bioscience (NASDAQ:RGC) Trading Up 10.5% – Time to Buy?

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) rose 10.5% during trading on Monday . The stock traded as high as $14.90 and last traded at $14.39. Approximately 55,658 shares traded hands during trading, a decline of 99% from the average daily volume of 8,361,396 shares. The stock had previously closed at $13.02.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Wednesday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Regencell Bioscience Trading Up 6.3%

The firm’s 50-day moving average price is $15.55.

Institutional Investors Weigh In On Regencell Bioscience

Several large investors have recently bought and sold shares of RGC. Greenfield Savings Bank acquired a new stake in shares of Regencell Bioscience in the second quarter worth approximately $187,000. Y Intercept Hong Kong Ltd purchased a new position in Regencell Bioscience in the 2nd quarter valued at $222,000. BNP Paribas Financial Markets acquired a new stake in Regencell Bioscience during the 2nd quarter worth $768,000. Squarepoint Ops LLC acquired a new stake in Regencell Bioscience during the 2nd quarter worth $1,701,000. Finally, Geode Capital Management LLC grew its holdings in shares of Regencell Bioscience by 5,637.5% during the second quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock worth $6,664,000 after buying an additional 384,250 shares in the last quarter. 0.13% of the stock is currently owned by hedge funds and other institutional investors.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.